Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Shares of Danish pharmaceutical giant Novo Nordisk surged close to 14% on Friday after the company announced positive results from early-stage trials for its once-weekly obesity treatment, amycretin.

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Novo Nordisk said a Phase 1b/2a clinical trial of amycretin, which activates both the GLP-1 and amylin receptors to help manage blood sugar and weight, achieved weight loss of 22% on a 20 milligram ...

The trial tested amycretin in its injectable form, but Novo Nordisk is also separately developing the drug in pill form. Investors cheered an early trial of the pill early last year that showed weight ...

With (almost) no fees and unlimited refunds for ATM charges, Novo business checking is a good option for small-business owners on the go. But Novo’s customer support is lacking, and you can’t ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Novo Nordisk (NVO) reported headline results from STEP UP, a phase 3b trial in the global STEP programme. The trial achieved primary ...

Målet er at øge antallet fra de nuværende 500 til 1.500 i 2030. Udvidelsen af uddannelserne er kæmpestort, siger Michael Halgren, der er produktionsdirektør hos Novo Nordisk i Kalundborg. - Det er ...